Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 1
2014 5
2015 4
2016 7
2017 5
2018 11
2019 8
2020 8
2021 10
2022 4
2023 7
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

62 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for george vkas
Your search for George Vokas retrieved no results
The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation.
Steffel J, Verhamme P, Potpara TS, Albaladejo P, Antz M, Desteghe L, Haeusler KG, Oldgren J, Reinecke H, Roldan-Schilling V, Rowell N, Sinnaeve P, Collins R, Camm AJ, Heidbüchel H; ESC Scientific Document Group. Steffel J, et al. Eur Heart J. 2018 Apr 21;39(16):1330-1393. doi: 10.1093/eurheartj/ehy136. Eur Heart J. 2018. PMID: 29562325
Non-vitamin K antagonist oral anticoagulants (NOACs) are an alternative for vitamin K antagonists (VKAs) to prevent stroke in patients with atrial fibrillation (AF) and have emerged as the preferred choice, particularly in patients newly started on anticoagulation. ...
Non-vitamin K antagonist oral anticoagulants (NOACs) are an alternative for vitamin K antagonists (VKAs) to prevent stroke in patient …
The use of novel oral anticoagulants compared to vitamin K antagonists (warfarin) in patients with left ventricular thrombus after acute myocardial infarction.
Jones DA, Wright P, Alizadeh MA, Fhadil S, Rathod KS, Guttmann O, Knight C, Timmis A, Baumbach A, Wragg A, Mathur A, Antoniou S. Jones DA, et al. Eur Heart J Cardiovasc Pharmacother. 2021 Sep 21;7(5):398-404. doi: 10.1093/ehjcvp/pvaa096. Eur Heart J Cardiovasc Pharmacother. 2021. PMID: 32730627
CONCLUSION: These data suggest improved thrombus resolution in post-acute coronary syndrome (ACS) LV thrombosis in patients treated with NOACs compared to VKAs. This improvement in thrombus resolution was accompanied with a better safety profile for NOAC patients vs. ...
CONCLUSION: These data suggest improved thrombus resolution in post-acute coronary syndrome (ACS) LV thrombosis in patients treated with NOA …
Bleeding and related mortality with NOACs and VKAs in newly diagnosed atrial fibrillation: results from the GARFIELD-AF registry.
Bassand JP, Virdone S, Badoz M, Verheugt FWA, Camm AJ, Cools F, Fox KAA, Goldhaber SZ, Goto S, Haas S, Hacke W, Kayani G, Misselwitz F, Pieper KS, Turpie AGG, van Eickels M, Kakkar AK. Bassand JP, et al. Blood Adv. 2021 Feb 23;5(4):1081-1091. doi: 10.1182/bloodadvances.2020003560. Blood Adv. 2021. PMID: 33606006 Free PMC article.
One-year follow-up event rates (95% confidence interval [CI]) of minor, clinically relevant nonmajor (CRNM), and major bleedings were 2.29 (2.16-2.43), 1.10 (1.01-1.20), and 1.31 (1.21-1.41) per 100 patient-years, respectively. Bleeding risk was lower with NOACs than VKAs …
One-year follow-up event rates (95% confidence interval [CI]) of minor, clinically relevant nonmajor (CRNM), and major bleedings were 2.29 ( …
Recent evidence for direct oral anticoagulants in chronic kidney disease.
Ha JT, Badve SV, Jun M. Ha JT, et al. Curr Opin Nephrol Hypertens. 2019 May;28(3):251-261. doi: 10.1097/MNH.0000000000000493. Curr Opin Nephrol Hypertens. 2019. PMID: 30789840 Review.
RECENT FINDINGS: Data on early-to-moderate stage CKD derived from pivotal randomized controlled trials in broader atrial fibrillation and VTE populations support the favorable risk-benefit ratio of DOACs compared with VKAs in patients in these groups. However, safety data …
RECENT FINDINGS: Data on early-to-moderate stage CKD derived from pivotal randomized controlled trials in broader atrial fibrillation and VT …
State of play and future direction with NOACs: An expert consensus.
Cohen AT, Lip GY, De Caterina R, Heidbuchel H, Zamorano JL, Agnelli G, Verheugt F, Camm AJ. Cohen AT, et al. Vascul Pharmacol. 2018 Jul;106:9-21. doi: 10.1016/j.vph.2018.04.001. Epub 2018 Apr 12. Vascul Pharmacol. 2018. PMID: 29656119 Free article. Review.
In both, the use of anticoagulation with vitamin K antagonists (VKAs) has been traditionally used to prevent adverse events. However, VKA therapy is associated with challenges relating to dose maintenance, the need to monitor anticoagulation, and bleeding risks. ...
In both, the use of anticoagulation with vitamin K antagonists (VKAs) has been traditionally used to prevent adverse events. However, …
Oral Anticoagulant Treatment in Patients with Atrial Fibrillation and Chronic Kidney Disease.
Stoica MC, Gáll Z, Gliga ML, Căldăraru CD, Székely O. Stoica MC, et al. Medicina (Kaunas). 2021 Apr 27;57(5):422. doi: 10.3390/medicina57050422. Medicina (Kaunas). 2021. PMID: 33925501 Free PMC article. Review.
As a result, a number of nonvitamin K antagonist oral anticoagulants (NOAC) that directly target the enzymatic activity of factor II and factor Xa have been successfully licensed providing a more predictable effect and better safety profile compared to conventional anticoagulants …
As a result, a number of nonvitamin K antagonist oral anticoagulants (NOAC) that directly target the enzymatic activity of factor II and fac …
Methods to Correct Drug-Induced Coagulopathy in Bleeding Emergencies: A Comparative Review.
Nalezinski S. Nalezinski S. Lab Med. 2022 Jul 4;53(4):336-343. doi: 10.1093/labmed/lmab115. Lab Med. 2022. PMID: 35073576 Review.
Vitamin K has been proven to reliably and effectively reverse the effect of vitamin K antagonists (VKAs) while having a lower anaphylactoid risk than frozen plasma. ...Frozen plasma is not recommended as a first-line treatment for the reversal of VKAs. Novel anticoa …
Vitamin K has been proven to reliably and effectively reverse the effect of vitamin K antagonists (VKAs) while having a lower anaphyl …
Long-term treatment of cancer-associated thrombosis: the choice of the optimal anticoagulant.
Elalamy I, Mahé I, Ageno W, Meyer G. Elalamy I, et al. J Thromb Haemost. 2017 May;15(5):848-857. doi: 10.1111/jth.13659. Epub 2017 Mar 21. J Thromb Haemost. 2017. PMID: 28222250 Free article. Review.
Compared with VKAs, non-vitamin-K antagonist oral anticoagulants or direct oral anticoagulants (DOACs) are more target specific and do not require laboratory monitoring, whereas the oral route of administration makes them potentially attractive alternatives to LMWH. In ran …
Compared with VKAs, non-vitamin-K antagonist oral anticoagulants or direct oral anticoagulants (DOACs) are more target specific and d …
Direct oral anticoagulants versus standard triple therapy in atrial fibrillation and PCI: meta-analysis.
Brunetti ND, Tarantino N, De Gennaro L, Correale M, Santoro F, Di Biase M. Brunetti ND, et al. Open Heart. 2018 Jul 3;5(2):e000785. doi: 10.1136/openhrt-2018-000785. eCollection 2018. Open Heart. 2018. PMID: 30018775 Free PMC article. Review.
When compared with patients receiving standard triple therapy (vitamin-K antagonists plus double antiplatelet therapy [VKAs plus DAPT]), patients receiving DOACs (rivaroxaban/dabigatran plus either one or two antiplatelet agents) had a statistically significant lower risk …
When compared with patients receiving standard triple therapy (vitamin-K antagonists plus double antiplatelet therapy [VKAs plus DAPT …
[Treatment and Secondary Prevention of Venous Thromboembolism - Change in Oral Anticoagulation].
Helms TM, Gulba D, Ahrens I, Schäfer A, Hankowitz J, Kuhlencordt P, Lipp HP, Nikol S, Riess H, Stargardt T, Bramlage P. Helms TM, et al. Dtsch Med Wochenschr. 2017 Jul;142(13):986-993. doi: 10.1055/s-0042-124132. Epub 2017 Apr 19. Dtsch Med Wochenschr. 2017. PMID: 28423431 Review. German.
In patients with renal insufficiency the dose of all NOACs should be reduced similarly to NMH/FDX. In contrast to VKAs, bridging with NOACs in case of surgical interventions is generally dispensable. ...
In patients with renal insufficiency the dose of all NOACs should be reduced similarly to NMH/FDX. In contrast to VKAs, bridging with …
62 results